Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06964087 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
A Phase 2 study of Type I Diabetes, sponsored by Op-T.
- Active
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT06964087 is a Phase 2 study of Type I Diabetes that is active but no longer recruiting, run by Op-T. The registered enrollment target is 72 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06964087, a Phase 2 study of Type I Diabetes, is active but no longer recruiting, sponsored by Op-T.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
Conditions Studied
Interventions
- DRUG OPT101
- OTHER OPT101 Placebo to Match (PTM)
Study Locations (1)
Washington
- Rainier Clinical Research Center - Renton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2028-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06964087
The ClinicalTrials.gov registry entry for NCT06964087 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Op-T, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type I Diabetes appearing as the primary indexed condition, and to 2 interventions - of which OPT101 is the first listed.
NCT06964087 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT06964087 about?
NCT06964087 is a clinical study titled "Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus". This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
What is the current status of trial NCT06964087?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2025-05-27. Estimated completion is 2028-08-19.
What conditions does trial NCT06964087 study?
This clinical trial studies the following conditions: Type I Diabetes.
What interventions are being tested in trial NCT06964087?
The interventions under investigation include: OPT101 (DRUG), OPT101 Placebo to Match (PTM) (OTHER).
Who is sponsoring clinical trial NCT06964087?
This trial is sponsored by Op-T, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06964087 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type I Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.